Jade Biosciences: Pay

Jade Biosciences paid its 4 named executives $20.3M in total in FY2025 (Dec). CEO Tom Frohlich was paid $9.8M of that.

Pay$100 in the stock at the end of FY23 → $19
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Tom FrohlichChief Executive Officer, President and Director
FY2025 (Dec)
FY2024 (Dec)
2 years
Andrew King, Ph.D.President, Research and Development
FY2025 (Dec)
FY2024 (Dec)
2 years
Bradford DahmsChief Financial Officer
FY2025 (Dec)
1 year
Timothy NoyesFormer Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $5.5M. CEO pay of Jade Biosciences for that year is not on file.

  1. 1Kymera Therapeutics
  2. 2Spyre Therapeutics
  3. 3Lyell Immunopharma
  4. 4Oruka Therapeutics
  5. 5Jade BiosciencesNot disclosed
  6. 6ACELYRIN, Inc.Not disclosed
  7. 7AlumisNot disclosed
  8. 8Apogee Therapeutics, Inc.Not disclosed
  9. 9Astria Therapeutics, Inc.Not disclosed
  10. 10CARGO Therapeutics, Inc.Not disclosed
  11. 11Contineum Therapeutics, Inc.Not disclosed
  12. 12Dianthus Therapeutics, Inc.Not disclosed
  13. 13Entrada TherapeuticsNot disclosed
  14. 14Janux TherapeuticsNot disclosed
  15. 15Kyverna Therapeutics, Inc.Not disclosed
  16. 16Pliant Therapeutics, Inc.Not disclosed
  17. 17Prime MedicineNot disclosed
  18. 18Septerna Therapeutics, Inc.Not disclosed
  19. 19Third Harmonic Bio, Inc.Not disclosed
  20. 20Upstream BioNot disclosed
  21. 21Zenas BioPharmaNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.